|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||3.0000 - 3.0100|
|52-week range||3.0000 - 11.0000|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.00|
BOSTON & SEONGNAM, S. Korea & SHANGHAI/SUZHOU, China, October 08, 2021--CTX-009 (ABL001/ES104) clinical data presented today at the New Drugs on the Horizon plenary session of 2021 AACR-NCI-EORTC International Conference
BOSTON, October 01, 2021--CTX-009 clinical data was selected to be a Plenary Presentation at the AACR-NCI-EORTC international conference.
BOSTON, August 13, 2021--Thomas Schuetz, MD, PhD, Co-Founder and CEO of Compass Therapeutics will participate in a fireside chat at the Citi 16th Annual Biopharma Conference.